Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alcon Inc (DE:2U3)
XETRA:2U3
Holding DE:2U3?
Track your performance easily
2U3 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€53.03 - €54.33
Previous Close€54.33
Volume3.00K
Average Volume (3M)3.00K
Market Cap
€40.74B
Enterprise Value€44.63B
Total Cash (Recent Filing)$1.10B
Total Debt (Recent Filing)$5.15B
Price to Earnings (P/E)25.0
BetaN/A
Next Earnings
Mar 03, 2025EPS Estimate
€0.67Last Dividend Ex-Date
May 14, 2024Dividend Yield0.32%
Share Statistics
EPS (TTM)2.17
Shares Outstanding499,700,000
10 Day Avg. Volume0
30 Day Avg. Volume3,001
Standard Deviation0.02
R-Squared0.10
Alpha0.00995
Financial Highlights & Ratios
Price to Book (P/B)1.38
Price to Sales (P/S)5.54
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue10.24
Enterprise Value/Gross Profit8.51
Enterprise Value/Ebitda47.32
Forecast
1Y Price Target
€95.90Price Target Upside76.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Alcon News
PremiumCompany Announcements
Alcon Delivers Strong Q3 2024 Earnings Growth
PremiumCompany Announcements
Alcon’s Strong Q3 2024 Results Boost Investor Confidence
PremiumThe Fly
Alcon trading resumesBulls Say, Bears Say
Bulls Say
Financial PerformanceCore EPS of $0.81 was above BTIG/Consensus estimates, indicating better-than-expected profitability.
Market PositionAlcon is a leader in the $30B+ ophthalmic device market, holding a #1/#2 position across most surgical and vision care categories in which it competes.
Product LaunchesALC's product launch lineup is one of the best it's been since its spin from Novartis and is expected to result in revenue growth accelerating, driving multiple expansion as margin and earnings outlook strengthens.
Bears Say
Earnings PerformanceALC lowered its 2024 sales and EPS guidance, reflecting adjustments in expected growth rates and margins.
Financial GuidanceManagement lowered the midpoint of its previously expected 2024 revenue outlook to +6-7% y/y cc vs. +7-9% previously.
Market CompetitionALC's competition is closing the gap, such as JNJ's US contact lens growth of +10.2% in 3Q24 and BLCO's outperformance.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
13.24% Mutual Funds
18.44% Other Institutional Investors
56.59% Public Companies and
Individual Investors
2U3 FAQ
What was Alcon Inc’s price range in the past 12 months?
Alcon Inc lowest stock price was €53.03 and its highest was €54.33 in the past 12 months.
What is Alcon Inc’s market cap?
Currently, no data Available
When is Alcon Inc’s upcoming earnings report date?
Alcon Inc’s upcoming earnings report date is Mar 03, 2025 which is in 71 days.
How were Alcon Inc’s earnings last quarter?
Alcon Inc released its earnings results on Nov 12, 2024. The company reported €0.767 earnings per share for the quarter, beating the consensus estimate of €0.685 by €0.082.
Is Alcon Inc overvalued?
According to Wall Street analysts Alcon Inc’s price is currently Undervalued.
Does Alcon Inc pay dividends?
Alcon Inc pays a Annually dividend of €0.257 which represents an annual dividend yield of 0.32%. See more information on Alcon Inc dividends here
What is Alcon Inc’s EPS estimate?
Alcon Inc’s EPS estimate is €0.67.
How many shares outstanding does Alcon Inc have?
Alcon Inc has 499,700,000 shares outstanding.
What happened to Alcon Inc’s price movement after its last earnings report?
Alcon Inc reported an EPS of €0.767 in its last earnings report, beating expectations of €0.685. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Alcon Inc?
Among the largest hedge funds holding Alcon Inc’s share is Antipodes Partners Ltd. It holds Alcon Inc’s shares valued at 108M.
---
Alcon Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€95.90 (76.51% Upside)
€95.90 (76.51% Upside)
Blogger Sentiment
Bullish
DE:2U3 Sentiment 100%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
13.77%
12-Months-Change
Fundamentals
Return on Equity
5.59%
Trailing 12-Months
Asset Growth
3.38%
Trailing 12-Months
Company Description
Alcon Inc
Alcon Inc. is a medical company which is specialized in eye care products. The company develops, manufactures, distributes, and sells technologies and devices for cataract, retinal, refractive surgery, as well as contact lenses and lens care products.
---
2U3 Company Deck
---
2U3 Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook for Alcon, with notable achievements in product innovation and strategic partnerships offset by challenges in the U.S. surgical market and competitive pressures. The company showed strong financial performance and promising growth in international markets, but faced headwinds in the U.S. that impacted guidance and margins.Read More>---
2U3 Stock 12 Month Forecast
Average Price Target
€95.90
▲(76.51% Upside)
Technical Analysis
Best Analysts Covering 2U3
1 Year
1 Year Success Rate
10/16 ratings generated profit
1 Year Average Return
+7.06%
reiterated a buy rating last month
Copying Anthony Petrone's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +7.06% per trade.
---